Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Cytokinetics Inc

NASDAQ: CYTK · Life Sciences · 8 alerts · CIK 1061983

Share price
$53.17Close, Nov 16
Market cap
$7.41B
Shares outstanding
139.3MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Cytokinetics Inc filings on SEC EDGAR ↗

4:32 PM ET 10-Q
Financial Results

Cytokinetics Q3 2026 Results: Net Loss of $190M, Loss Narrows

Cytokinetics filed its 10-Q for the period ending September 30, 2026, reporting 139,303,351 shares of common stock outstanding as of November 2, 2026. The company continues to advance its clinical pipeline, including aficamten and omecamtiv mecarbil, supported by various financing and royalty agreements with Royalty Pharma and Bayer.

Key figure
Net loss $190M
4:06 PM ET 8-K
Financial Results

Cytokinetics Financial Results

Cytokinetics reported Q3 2026 financial results, highlighted by $44.5 million in net product revenue from MYQORZO (aficamten). The company ended the quarter with approximately $1.6 billion in cash and plans to submit a supplemental NDA for aficamten in non-obstructive HCM in Q4 2026.

Term
Q3 2026

“Our third quarter results demonstrate continued strong execution as Cytokinetics enters its next phase of growth as a global specialty cardiology biopharmaceutical company.”

Robert I. Blum, Cytokinetics’ President and Chief Executive Officer

“In the U.S., the launch of MYQORZO continued to build solid momentum and increased velocity with growing adoption across a broadening base of prescribers.”

Robert I. Blum, Cytokinetics’ President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.